<unk>  is a combination of<unk><unk>  with an<unk> agonist/antagonist that is FDA approved for the treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.
Conjugated estrogens/bazedoxifene
Tamoxifen
Enzalutamide
Bicalutamide
Flutamide
Selective estrogen receptor modulator
Anastrozole
Nilutamide